Journal de Pharmacie Clinique
MENUMetastatic non-small-cell lung cancer treatment: which chemotherapy? Volume 26, issue 1, Janvier-Février-Mars 2007
Figures
Service pharmacie, Hôpital européen Georges Pompidou, HEGP, AP-HP, 20, rue Leblanc, 75015 Paris, Service d’oncologie médicale, Hôpital européen Georges Pompidou, HEGP, AP-HP, 20, rue Leblanc, 75015 Paris
- Key words: non-small-cell lung cancer, chemotherapy, palliative care, therapeutic strategy, quality of life, targeted therapies
- DOI : 10.1684/jpc.2007.0034
- Page(s) : 15-24
- Published in: 2007
The therapeutic strategy of metastatic non-small-cell lung cancer (NSCLC) has known a qualitative evolution these last ten years. The added value of chemotherapy versus palliative care has been demonstrated by several meta-analyses. New molecules with better efficacy-toxicity ratio (vinorelbine, paclitaxel, docetaxel, gemcitabine, pemetrexed) improved the therapeutic strategy according to the patient performance status. Platinum-based combination remains the standard of care in first line treatment with a median survival of 8 months and a one-year median survival of 35%, while no particular doublet shown its superiority. Currently, a second line treatment is a standard. Regarding targeted therapies, their role in NSCLC are under way.